Small interfering RNA (siRNA) is a form of genetic medicine that can silence or knock out any overexpressed genes in disease.It's also called short interfering RNA.These rnas are widely used to assess the specific contributions of genes to a variety of cell phenotypes, including apoptosis, pancreatic bird signaling, cytokinesis, and cell differentiation.They are used to identify novel pathways and have a meaningful impact on the identification of targets for several diseases (such as AIDS, cancer and hepatitis) and cellular processes.The mechanism of action of siRNA involves introducing it into cells.SiRNA sequences should be designed to match the short regions of the target gene.Small interfering rnas are processed by the cell's own enzymes to eliminate the mRNA of the target gene, thereby preventing overexpression of the pathogenic gene.It is based on the natural response of cells when they detect genetic abnormalities or infections.It has some advantages over the different types of therapies currently available, such as target specificity, reduced secondary effects, and high specificity.The preclinical development duration of small interfering RNA compounds (about 15 to 24 months) is shorter than that of monoclonal antibodies (about 27 to 50 months) or other traditional small molecules (about 42 to 66 months).The shortening of preclinical stage is attributed to the rational design of RNA.The design includes mathematical algorithms assembled in software to select the most appropriate RNA sequence to silence specific genetic targets.They are usually more effective than other traditional medicines.SiRNA therapy includes liposome-based systemic therapy and nanoparticle based systemic therapy.Liposome-based systems are associated with liver-targeted pharmacokinetics, which limits the therapeutic potential of siRNA therapy to other common liver diseases, such as hepatocellular carcinoma, hepatitis, and hypercholesterolemia.
Market Analysis and Insights: Global Small Interfering RNA (siRNA) Therapeutics Market
The global Small Interfering RNA (siRNA) Therapeutics market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Small Interfering RNA (siRNA) Therapeutics market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Small Interfering RNA (siRNA) Therapeutics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Small Interfering RNA (siRNA) Therapeutics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Small Interfering RNA (siRNA) Therapeutics revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Small Interfering RNA (siRNA) Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Small Interfering RNA (siRNA) Therapeutics revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
GE
Horizon Discovery
Thermo Scientific
OPKO Health
AInylam Pharmaceuticals
Arrowhead Research
Sanofi Genzyme
Genecon Biotechnologies
Arbutus Biopharma
Silent Therapeutics
Sylentis
Segment by Type
Liposome Based Systemic Therapy
Nanoparticle Based Systemic Therapy
Other
Segment by Application
Hospital
Research Institutions
Pharmaceutical and Biotechnology Companies
Academic Institutions
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Small Interfering RNA (siRNA) Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Small Interfering RNA (siRNA) Therapeutics companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Small Interfering RNA (siRNA) Therapeutics revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Small Interfering RNA (siRNA) Therapeutics Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Liposome Based Systemic Therapy
1.2.3 Nanoparticle Based Systemic Therapy
1.2.4 Other
1.3 Market by Application
1.3.1 Global Small Interfering RNA (siRNA) Therapeutics Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Research Institutions
1.3.4 Pharmaceutical and Biotechnology Companies
1.3.5 Academic Institutions
1.3.6 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Small Interfering RNA (siRNA) Therapeutics Market Perspective (2019-2030)
2.2 Global Small Interfering RNA (siRNA) Therapeutics Growth Trends by Region
2.2.1 Small Interfering RNA (siRNA) Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Small Interfering RNA (siRNA) Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Small Interfering RNA (siRNA) Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Small Interfering RNA (siRNA) Therapeutics Market Dynamics
2.3.1 Small Interfering RNA (siRNA) Therapeutics Industry Trends
2.3.2 Small Interfering RNA (siRNA) Therapeutics Market Drivers
2.3.3 Small Interfering RNA (siRNA) Therapeutics Market Challenges
2.3.4 Small Interfering RNA (siRNA) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Small Interfering RNA (siRNA) Therapeutics by Players
3.1.1 Global Small Interfering RNA (siRNA) Therapeutics Revenue by Players (2019-2024)
3.1.2 Global Small Interfering RNA (siRNA) Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Small Interfering RNA (siRNA) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Small Interfering RNA (siRNA) Therapeutics, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Small Interfering RNA (siRNA) Therapeutics Market Concentration Ratio
3.4.1 Global Small Interfering RNA (siRNA) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Small Interfering RNA (siRNA) Therapeutics Revenue in 2023
3.5 Global Key Players of Small Interfering RNA (siRNA) Therapeutics Head office and Area Served
3.6 Global Key Players of Small Interfering RNA (siRNA) Therapeutics, Product and Application
3.7 Global Key Players of Small Interfering RNA (siRNA) Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Small Interfering RNA (siRNA) Therapeutics Breakdown Data by Type
4.1 Global Small Interfering RNA (siRNA) Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Small Interfering RNA (siRNA) Therapeutics Forecasted Market Size by Type (2025-2030)
5 Small Interfering RNA (siRNA) Therapeutics Breakdown Data by Application
5.1 Global Small Interfering RNA (siRNA) Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Small Interfering RNA (siRNA) Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Small Interfering RNA (siRNA) Therapeutics Market Size (2019-2030)
6.2 North America Small Interfering RNA (siRNA) Therapeutics Market Size by Type
6.2.1 North America Small Interfering RNA (siRNA) Therapeutics Market Size by Type (2019-2024)
6.2.2 North America Small Interfering RNA (siRNA) Therapeutics Market Size by Type (2025-2030)
6.2.3 North America Small Interfering RNA (siRNA) Therapeutics Market Share by Type (2019-2030)
6.3 North America Small Interfering RNA (siRNA) Therapeutics Market Size by Application
6.3.1 North America Small Interfering RNA (siRNA) Therapeutics Market Size by Application (2019-2024)
6.3.2 North America Small Interfering RNA (siRNA) Therapeutics Market Size by Application (2025-2030)
6.3.3 North America Small Interfering RNA (siRNA) Therapeutics Market Share by Application (2019-2030)
6.4 North America Small Interfering RNA (siRNA) Therapeutics Market Size by Country
6.4.1 North America Small Interfering RNA (siRNA) Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Small Interfering RNA (siRNA) Therapeutics Market Size by Country (2019-2024)
6.4.3 North America Small Interfering RNA (siRNA) Therapeutics Market Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Small Interfering RNA (siRNA) Therapeutics Market Size (2019-2030)
7.2 Europe Small Interfering RNA (siRNA) Therapeutics Market Size by Type
7.2.1 Europe Small Interfering RNA (siRNA) Therapeutics Market Size by Type (2019-2024)
7.2.2 Europe Small Interfering RNA (siRNA) Therapeutics Market Size by Type (2025-2030)
7.2.3 Europe Small Interfering RNA (siRNA) Therapeutics Market Share by Type (2019-2030)
7.3 Europe Small Interfering RNA (siRNA) Therapeutics Market Size by Application
7.3.1 Europe Small Interfering RNA (siRNA) Therapeutics Market Size by Application (2019-2024)
7.3.2 Europe Small Interfering RNA (siRNA) Therapeutics Market Size by Application (2025-2030)
7.3.3 Europe Small Interfering RNA (siRNA) Therapeutics Market Share by Application (2019-2030)
7.4 Europe Small Interfering RNA (siRNA) Therapeutics Market Size by Country
7.4.1 Europe Small Interfering RNA (siRNA) Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Small Interfering RNA (siRNA) Therapeutics Market Size by Country (2019-2024)
7.4.3 Europe Small Interfering RNA (siRNA) Therapeutics Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Small Interfering RNA (siRNA) Therapeutics Market Size (2019-2030)
8.2 China Small Interfering RNA (siRNA) Therapeutics Market Size by Type
8.2.1 China Small Interfering RNA (siRNA) Therapeutics Market Size by Type (2019-2024)
8.2.2 China Small Interfering RNA (siRNA) Therapeutics Market Size by Type (2025-2030)
8.2.3 China Small Interfering RNA (siRNA) Therapeutics Market Share by Type (2019-2030)
8.3 China Small Interfering RNA (siRNA) Therapeutics Market Size by Application
8.3.1 China Small Interfering RNA (siRNA) Therapeutics Market Size by Application (2019-2024)
8.3.2 China Small Interfering RNA (siRNA) Therapeutics Market Size by Application (2025-2030)
8.3.3 China Small Interfering RNA (siRNA) Therapeutics Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Small Interfering RNA (siRNA) Therapeutics Market Size (2019-2030)
9.2 Asia Small Interfering RNA (siRNA) Therapeutics Market Size by Type
9.2.1 Asia Small Interfering RNA (siRNA) Therapeutics Market Size by Type (2019-2024)
9.2.2 Asia Small Interfering RNA (siRNA) Therapeutics Market Size by Type (2025-2030)
9.2.3 Asia Small Interfering RNA (siRNA) Therapeutics Market Share by Type (2019-2030)
9.3 Asia Small Interfering RNA (siRNA) Therapeutics Market Size by Application
9.3.1 Asia Small Interfering RNA (siRNA) Therapeutics Market Size by Application (2019-2024)
9.3.2 Asia Small Interfering RNA (siRNA) Therapeutics Market Size by Application (2025-2030)
9.3.3 Asia Small Interfering RNA (siRNA) Therapeutics Market Share by Application (2019-2030)
9.4 Asia Small Interfering RNA (siRNA) Therapeutics Market Size by Region
9.4.1 Asia Small Interfering RNA (siRNA) Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Small Interfering RNA (siRNA) Therapeutics Market Size by Region (2019-2024)
9.4.3 Asia Small Interfering RNA (siRNA) Therapeutics Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Small Interfering RNA (siRNA) Therapeutics Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Small Interfering RNA (siRNA) Therapeutics Market Size by Type
10.2.1 Middle East, Africa, and Latin America Small Interfering RNA (siRNA) Therapeutics Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Small Interfering RNA (siRNA) Therapeutics Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Small Interfering RNA (siRNA) Therapeutics Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Small Interfering RNA (siRNA) Therapeutics Market Size by Application
10.3.1 Middle East, Africa, and Latin America Small Interfering RNA (siRNA) Therapeutics Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Small Interfering RNA (siRNA) Therapeutics Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Small Interfering RNA (siRNA) Therapeutics Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Small Interfering RNA (siRNA) Therapeutics Market Size by Country
10.4.1 Middle East, Africa, and Latin America Small Interfering RNA (siRNA) Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Small Interfering RNA (siRNA) Therapeutics Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Small Interfering RNA (siRNA) Therapeutics Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 GE
11.1.1 GE Company Details
11.1.2 GE Business Overview
11.1.3 GE Small Interfering RNA (siRNA) Therapeutics Introduction
11.1.4 GE Revenue in Small Interfering RNA (siRNA) Therapeutics Business (2019-2024)
11.1.5 GE Recent Developments
11.2 Horizon Discovery
11.2.1 Horizon Discovery Company Details
11.2.2 Horizon Discovery Business Overview
11.2.3 Horizon Discovery Small Interfering RNA (siRNA) Therapeutics Introduction
11.2.4 Horizon Discovery Revenue in Small Interfering RNA (siRNA) Therapeutics Business (2019-2024)
11.2.5 Horizon Discovery Recent Developments
11.3 Thermo Scientific
11.3.1 Thermo Scientific Company Details
11.3.2 Thermo Scientific Business Overview
11.3.3 Thermo Scientific Small Interfering RNA (siRNA) Therapeutics Introduction
11.3.4 Thermo Scientific Revenue in Small Interfering RNA (siRNA) Therapeutics Business (2019-2024)
11.3.5 Thermo Scientific Recent Developments
11.4 OPKO Health
11.4.1 OPKO Health Company Details
11.4.2 OPKO Health Business Overview
11.4.3 OPKO Health Small Interfering RNA (siRNA) Therapeutics Introduction
11.4.4 OPKO Health Revenue in Small Interfering RNA (siRNA) Therapeutics Business (2019-2024)
11.4.5 OPKO Health Recent Developments
11.5 AInylam Pharmaceuticals
11.5.1 AInylam Pharmaceuticals Company Details
11.5.2 AInylam Pharmaceuticals Business Overview
11.5.3 AInylam Pharmaceuticals Small Interfering RNA (siRNA) Therapeutics Introduction
11.5.4 AInylam Pharmaceuticals Revenue in Small Interfering RNA (siRNA) Therapeutics Business (2019-2024)
11.5.5 AInylam Pharmaceuticals Recent Developments
11.6 Arrowhead Research
11.6.1 Arrowhead Research Company Details
11.6.2 Arrowhead Research Business Overview
11.6.3 Arrowhead Research Small Interfering RNA (siRNA) Therapeutics Introduction
11.6.4 Arrowhead Research Revenue in Small Interfering RNA (siRNA) Therapeutics Business (2019-2024)
11.6.5 Arrowhead Research Recent Developments
11.7 Sanofi Genzyme
11.7.1 Sanofi Genzyme Company Details
11.7.2 Sanofi Genzyme Business Overview
11.7.3 Sanofi Genzyme Small Interfering RNA (siRNA) Therapeutics Introduction
11.7.4 Sanofi Genzyme Revenue in Small Interfering RNA (siRNA) Therapeutics Business (2019-2024)
11.7.5 Sanofi Genzyme Recent Developments
11.8 Genecon Biotechnologies
11.8.1 Genecon Biotechnologies Company Details
11.8.2 Genecon Biotechnologies Business Overview
11.8.3 Genecon Biotechnologies Small Interfering RNA (siRNA) Therapeutics Introduction
11.8.4 Genecon Biotechnologies Revenue in Small Interfering RNA (siRNA) Therapeutics Business (2019-2024)
11.8.5 Genecon Biotechnologies Recent Developments
11.9 Arbutus Biopharma
11.9.1 Arbutus Biopharma Company Details
11.9.2 Arbutus Biopharma Business Overview
11.9.3 Arbutus Biopharma Small Interfering RNA (siRNA) Therapeutics Introduction
11.9.4 Arbutus Biopharma Revenue in Small Interfering RNA (siRNA) Therapeutics Business (2019-2024)
11.9.5 Arbutus Biopharma Recent Developments
11.10 Silent Therapeutics
11.10.1 Silent Therapeutics Company Details
11.10.2 Silent Therapeutics Business Overview
11.10.3 Silent Therapeutics Small Interfering RNA (siRNA) Therapeutics Introduction
11.10.4 Silent Therapeutics Revenue in Small Interfering RNA (siRNA) Therapeutics Business (2019-2024)
11.10.5 Silent Therapeutics Recent Developments
11.11 Sylentis
11.11.1 Sylentis Company Details
11.11.2 Sylentis Business Overview
11.11.3 Sylentis Small Interfering RNA (siRNA) Therapeutics Introduction
11.11.4 Sylentis Revenue in Small Interfering RNA (siRNA) Therapeutics Business (2019-2024)
11.11.5 Sylentis Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
GE
Horizon Discovery
Thermo Scientific
OPKO Health
AInylam Pharmaceuticals
Arrowhead Research
Sanofi Genzyme
Genecon Biotechnologies
Arbutus Biopharma
Silent Therapeutics
Sylentis
听
听
*If Applicable.
